Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gerard Ber Insider Profile
11 Followers
Gerard Ber, Director at Y-Mabs Therapeutics, holds 21.22K shares in Lantheus (Ticker: LNTH), holds 1.61K shares in Y-Mabs Therapeutics (Ticker: YMAB), holds 0.00 shares in Progenics (Ticker: PGNX).
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-18.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Gerard Ber
Gerard Ber's Trading History
Y-Mabs Therapeutics
Jun 11, 2024
Director
Informative Sell
8.66K
$13.31K
Progenics
Jun 23, 2020
―
Uninformative Sell
―
$0.00
Lantheus
Aug 14, 2024
Director
Uninformative Sell
1.50M
$1.89M
List of latest transactions for each holding click on a transaction to see Gerard Ber's performance on stock
You May Also Like
Gerard Ber insider profile FAQ
What is the percentage of profitable transactions made by Gerard Ber?
The percentage of profitable transactions made by Gerard Ber is 50%.
What is the average return per transaction made by Gerard Ber?
The average return per transaction made by Gerard Ber is -18.00%.
What stocks does Gerard Ber hold?
Gerard Ber holds: YMAB, PGNX, LNTH stocks.
What was Gerard Ber’s latest transaction?
Gerard Ber latest transaction was an Uninformative Sell of $1.50M.
What was Gerard Ber's most profitable transaction?
Gerard Ber’s most profitable transaction was an Informative Sell of YMAB stock on June 11, 2024. The return on the trade was 31.00%.
What is Gerard Ber's role in Y-Mabs Therapeutics?
Gerard Ber's role in Y-Mabs Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.